에이전스(AGEN) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

AGEN

Agenus Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$6.13

+0.15 ▲ +2.51%

🌙 7월 28일 8:08 AM ET (한국 7/28 21:08)

$6.02

-0.11 ▼ -1.84%

에이전스(AGEN) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$274M

스몰캡

P/E

3.7

저평가 구간

배당수익률

없음

52주 위치

57%

저점 +126% · 고점 -30%

애널리스트

적극 매수

C+

Fundamental health

vs. 초고성장주 초소형주

수익성

Top 4%

성장

Top 40%

밸류에이션

Top 68%

재무 안정

Top 96%

Index ⓘ	RUT	P/E ⓘ	3.67	EPS (ttm) ⓘ	1.67	Insider Own ⓘ	9.31%	Shs Outstand ⓘ	44.8M	Perf Week ⓘ	23.34%
Market Cap ⓘ	0.27B	Forward P/E ⓘ	-	EPS next Y ⓘ	-124.06%	Insider Trans ⓘ	-	Shs Float ⓘ	40.6M	Perf Month ⓘ	112.85%
Enterprise Value ⓘ	0.54B	PEG ⓘ	-	EPS next Q ⓘ	0.05	Inst Own ⓘ	27.65%	Short Float ⓘ	17.39%	Perf Quarter ⓘ	57.18%
Income ⓘ	0.06B	P/S ⓘ	2.21	EPS this Y ⓘ	135%	Inst Trans ⓘ	6.5%	Short Ratio ⓘ	1.78	Perf Half Y ⓘ	89.2%
Sales ⓘ	0.12B	P/B ⓘ	-	EPS next 5Y ⓘ	39.06%	ROA ⓘ	33.42%	Short Interest ⓘ	7.06M	Perf YTD ⓘ	95.22%
Book/sh ⓘ	-5.74	P/C ⓘ	7.84	EPS past 3/5Y ⓘ	93.99% 82.55%	ROE ⓘ	-	52W High ⓘ	-29.54% ($8.70)	Perf Year ⓘ	2.85%
Cash/sh ⓘ	0.78	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	5.22% 5.31%	ROIC ⓘ	-	52W Low ⓘ	126.2% ($2.71)	Perf 3Y ⓘ	-78.86%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	35.35	EPS Y/Y TTM ⓘ	120.02%	Gross Margin ⓘ	93.33%	Volatility(W/M) ⓘ	11.44% 13.27%	Perf 5Y ⓘ	-93.73%
Dividend TTM ⓘ	-	EV/Sales ⓘ	4.34	Sales Y/Y TTM ⓘ	24.46%	Oper. Margin ⓘ	6.3%	ATR (14) ⓘ	0.6	Perf 10Y ⓘ	-93.66%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	0.38	EPS Q/Q ⓘ	198.88%	Profit Margin ⓘ	51.98%	RSI (14) ⓘ	70.87	Recom ⓘ	1
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	0.38	Sales Q/Q ⓘ	40.18%	SMA20 ⓘ	35.53% ($4.52)	Beta ⓘ	1.38	Target Price ⓘ	$19
Payout ⓘ	-	Debt/Eq ⓘ	-	Earnings ⓘ	2026/5/11	SMA50 ⓘ	64.11% ($3.74)	Rel Volume ⓘ	0.31	Prev Close ⓘ	$5.98
Employees ⓘ	81	LT Debt/Eq ⓘ	-	EPS/Sales Surpr. ⓘ	-51.43% -73.98%	SMA200 ⓘ	64.95% ($3.72)	Avg Volume(3M) ⓘ	3.97M	Price ⓘ	$6.13
IPO ⓘ	2000/2/4	Option/Short ⓘ	Yes/Yes			Trades ⓘ	7763	Volume ⓘ	1,232,558	Change ⓘ	2.51%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $34M (YoY +40%) · 순이익 $39M (YoY +249%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Agenus Inc (AGEN) Investment Analysis

What kind of company is Agenus Inc?

에이전스(AGEN) 초고성장주

Healthcare · Biotechnology

Small-Cap — Low Volume, High Volatility

🧬 Agenus is a US clinical-stage biotech company focused on immuno-oncology. Building on its antibody-based immune checkpoint modulators and proprietary immune-enhancing (adjuvant) technology, the company is developing novel drug candidates targeting a range of solid tumors. Since its founding in 1994, Agenus has continued its research into cancer therapeutics leveraging immune mechanisms.

Learn more about Agenus Inc →

Market Cap

$0.3B

Approx. KRW 0.4 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank3811

Employees81people

IPO2000/02/04

Current Price$6.13 ≈ 8,398원

📌 RUT · NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 11일 (월) · 장 시작 전 EPS -51.4% 매출 -74.0%

🔔 Earnings release 2026년 3월 16일 (월) · 장 시작 전 EPS +71.3% 매출 +21.7%

Is it profitable?

Profitable but financially weak

High debt load may weigh on results in a downturn

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

6.3%

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology 초소형주 Median -778.0% · Top tier

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

52.0%

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology 초소형주 Median -911.1% · Top tier

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

93.3%

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology 초소형주 Median 53.4% · Top 14%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROA

Annual earnings relative to total company assets

33.4%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 초소형주 Median -59.3% · Top tier

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

Financial health — Debt & liquidity burden

Current Ratio

Liquid assets available to cover liabilities due within a year

0.38

✓ 위험

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

0.38

✓ 매우 부진

My positionBottom 5%

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$19.00

현재가 대비 +210.0%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

내년 EPS 예상 성장률

-124.1%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

+39.1%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance

Mixed beats and misses

예상 상회

예상 부합

예상 하회

50%

상회 비율

+25.3%

평균 서프라이즈

2026.05.11

하회

실적 $-0.03 · 예상 $1.80 -101.8%

2026.03.16

상회

실적 $0.68 · 예상 $-1.30 +152.4%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth

Mid-range within the industry

Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+135.0%

우수

My positionTop 5%

Low range Average High range

초고성장주 초소형주 Median 50.1% · Top tier

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

-124.1%

매우 부진

My positionBottom 5%

Low range Average High range

초고성장주 초소형주 Median 35.0% · Bottom tier

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

+39.1%

평균

My positionMid-range

Low range Average High range

초고성장주 초소형주 Median 44.8% · Bottom 37%

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+94.0%

우수

My positionTop 5%

Low range Average High range

초고성장주 초소형주 Median 27.5% · Top tier

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+82.5%

우수

My positionTop 5%

Low range Average High range

초고성장주 초소형주 Median 20.7% · Top tier

Past 5-Year Revenue

How much revenue grew over the past 5 years

+5.3%

부진

My positionBottom 25%

Low range Average High range

초고성장주 초소형주 Median 47.0% · Bottom 10%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+40.2%

양호

My positionMid-range

Low range Average High range

초고성장주 초소형주 Median 3.6% · Top 29%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -162%p below the market

AGEN -93.7% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-162.1%p

Significantly behind the market

vs Health Care (XLV)

-118.2%p

Significantly behind the sector average

1-year basis

vs S&P 500

-13.2%p

behind the market

vs Health Care (XLV)

-16.9%p

behind the sector average

Rank among peers

5-year return Upper-Mid (42%) Based on 245 peers

1-year return Top 23% Based on 315 peers

Current position within 52-week range

Low (-126.2%p) High (-29.5%p)

Current price is 126.2% above the 52-week low and 29.5% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-40.2%

Annualized volatility

125.2%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢

Current diagnosis · 2026-07-27

Uptrend zone

Current price $6.13 above the midline ($4.52). Normal upward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟢

Current diagnosis · 2026-07-27

Bullish momentum holding

MACD 0.703 > Signal 0.530 in positive zone + Hist positive (+0.173). Trend in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

⚠️

Current diagnosis · 2026-07-27

Overbought zone — short-term pullback possible

RSI 71.0 (above 70). Buying pressure is excessive, and profit-taking may emerge. Stoch %K is also 54.1.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Earnings·Vs. Sales, In line with peers on Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Cheap

🧾 Vs. Sales Cheap

💧 Vs. Cash Flow Mid-range

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

3.67x

✓ Very cheap

My positionTop 25%

Low range Average High range

Biotechnology median 15.34x · Top 15% — relatively cheap within the industry

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

2.21x

✓ Very cheap

My positionTop 25%

Low range Average High range

Biotechnology 초소형주 median 11.24x · Top 16% — relatively cheap within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

35.35x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology median 22.58x · Around the industry average

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

Analyst target price (reference)

$19.00 vs. current price +210.0%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology

Who owns it?

Ownership is broadly stable

Institutional net buying +6.5% · Short interest elevated 17.4% · Short interest up +3.5pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

+6.5%

Institutions net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 27.6%

Moderate institutional participation

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 9.3%

Meaningful insider stake

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 63.0%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

17.4%

Somewhat high

Healthcare 초소형주 Median 3.9%

Past 90 days 📈 +3.5%p increase

Short interest days to cover

1.8 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 44.8M주

Float (tradable shares) 40.6M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding AGEN

ETFs with the highest weightings · 3 total shown

IWC

iShares Micro-Cap ETF

0.02%

$1.4B

VTI

Vanguard Total Stock Market ETF

0.00%

$657.4B

VXF

Vanguard Extended Market Index ETF

0.00%

$30.4B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
AGEN This Stock	$274.3M	3.7 ▲	-	-	-	+2.5%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 에이전스(AGEN)?

에이전스(AGEN) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of AGEN?

The market cap of AGEN is approximately $274M, ranking 3,811 within its sector.

What is the P/E ratio of AGEN?

AGEN has a P/E ratio of approximately 3.7x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for AGEN?

AGEN has recorded a 52-week high of $8.70 and a low of $2.71.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.